Advertisement
Screener

ELI LILLY AND COMPANY (LLY) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

ELI LILLY AND COMPANY Research and Development Expense

ELI LILLY AND COMPANY (LLY) reported Research and Development Expense of $2.36 billion for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.

Discontinued › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2023-08-08

  • ELI LILLY AND COMPANY research and development expense for the quarter ending 2023-06-30 was $2.36B, a 32.25% increase year-over-year.
  • ELI LILLY AND COMPANY research and development expense for the quarter ending 2023-03-31 was $1.99B, a 23.29% increase year-over-year.
  • ELI LILLY AND COMPANY research and development expense for the quarter ending 2022-12-31 was $2.00B, a 5.14% increase year-over-year.
  • ELI LILLY AND COMPANY research and development expense for the quarter ending 2022-09-30 was $1.80B, a 5.72% increase year-over-year.
  • ELI LILLY AND COMPANY research and development expense for fiscal 2022 was $7.19B, a 3.75% increase from fiscal 2021.
  • ELI LILLY AND COMPANY research and development expense for fiscal 2021 was $6.93B, a 15.97% increase from fiscal 2020.
  • ELI LILLY AND COMPANY research and development expense for fiscal 2020 was $5.98B, a 6.82% increase from fiscal 2019.
  • ELI LILLY AND COMPANY research and development expense for fiscal 2019 was $5.59B, a 10.77% increase from fiscal 2018.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2023-06-30$2.36B
10-Q · filed 2023-08-08
$4.34B
10-Q · filed 2023-08-08
$6.34B
derived: sum of 3 quarters · filed 2023-08-08
$8.14B
derived: sum of 4 quarters · filed 2023-08-08
2023-03-31$1.99B
10-Q · filed 2023-04-27
$3.98B
derived: sum of 2 quarters · filed 2023-04-27
$5.78B
derived: sum of 3 quarters · filed 2023-04-27
$7.57B
derived: sum of 4 quarters · filed 2023-08-08
2022-12-31$2.00B
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
$3.80B
derived: sum of 2 quarters · filed 2023-02-22
$5.58B
derived: sum of 3 quarters · filed 2023-08-08
$7.19B
10-K · filed 2023-02-22
2022-09-30$1.80B
10-Q · filed 2022-11-01
$3.58B
derived: sum of 2 quarters · filed 2023-08-08
$5.19B
10-Q · filed 2022-11-01
$7.09B
derived: sum of 4 quarters · filed 2023-08-08
2022-06-30$1.78B
10-Q · filed 2023-08-08
$3.39B
10-Q · filed 2023-08-08
$5.29B
derived: sum of 3 quarters · filed 2023-08-08
$7.00B
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31$1.61B
10-Q · filed 2023-04-27
$3.51B
derived: sum of 2 quarters · filed 2023-04-27
$5.21B
derived: sum of 3 quarters · filed 2023-04-27
$6.87B
derived: sum of 4 quarters · filed 2023-04-27
2021-12-31$1.90B
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
$3.60B
derived: sum of 2 quarters · filed 2023-02-22
$5.26B
derived: sum of 3 quarters · filed 2023-02-22
$6.93B
10-K · filed 2023-02-22
$7.03B
10-K · filed 2022-02-23
2021-09-30$1.71B
10-Q · filed 2022-11-01
$1.71B
10-Q · filed 2021-10-27
$3.36B
derived: sum of 2 quarters · filed 2022-11-01
$5.03B
10-Q · filed 2022-11-01
$5.07B
10-Q · filed 2021-10-27
$6.76B
derived: sum of 4 quarters · filed 2023-02-22
2021-06-30$1.66B
10-Q · filed 2022-08-04
$1.67B
10-Q · filed 2021-08-03
$3.33B
10-Q · filed 2022-08-04
$3.36B
10-Q · filed 2021-08-03
$5.06B
derived: sum of 3 quarters · filed 2023-02-22
$6.52B
derived: sum of 4 quarters · filed 2023-02-22
2021-03-31$1.67B
10-Q · filed 2022-04-29
$1.68B
10-Q · filed 2021-04-30
$3.40B
derived: sum of 2 quarters · filed 2023-02-22
$4.87B
derived: sum of 3 quarters · filed 2023-02-22
$6.26B
derived: sum of 4 quarters · filed 2023-02-22
2020-12-31$1.73B
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
$3.19B
derived: sum of 2 quarters · filed 2023-02-22
$4.58B
derived: sum of 3 quarters · filed 2023-02-22
$5.98B
10-K · filed 2023-02-22
$6.09B
10-K · filed 2021-02-17
2020-09-30$1.47B
10-Q · filed 2021-10-27
$2.86B
derived: sum of 2 quarters · filed 2021-10-27
$4.25B
10-Q · filed 2021-10-27
$5.83B
derived: sum of 4 quarters · filed 2022-02-23
2020-06-30$1.39B
10-Q · filed 2021-08-03
$2.78B
10-Q · filed 2021-08-03
$4.36B
derived: sum of 3 quarters · filed 2022-02-23
$5.74B
derived: sum of 4 quarters · filed 2022-02-23
2020-03-31$1.39B
10-Q · filed 2021-04-30
$2.97B
derived: sum of 2 quarters · filed 2022-02-23
$4.35B
derived: sum of 3 quarters · filed 2022-02-23
$5.76B
derived: sum of 4 quarters · filed 2022-02-23
2019-12-31$1.58B
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23
$2.96B
derived: sum of 2 quarters · filed 2022-02-23
$4.36B
derived: sum of 3 quarters · filed 2022-02-23
$5.59B
10-K · filed 2022-02-23
2019-09-30$1.38B
10-Q · filed 2020-10-28
$2.78B
derived: sum of 2 quarters · filed 2020-10-28
$4.01B
10-Q · filed 2020-10-28
$5.41B
derived: sum of 4 quarters · filed 2021-02-17
2019-06-30$1.40B
10-Q · filed 2020-07-31
$2.63B
10-Q · filed 2020-07-31
$4.02B
derived: sum of 3 quarters · filed 2021-02-17
$5.31B
derived: sum of 4 quarters · filed 2021-02-17
2019-03-31$1.23B
10-Q · filed 2020-05-01
$2.62B
derived: sum of 2 quarters · filed 2021-02-17
$3.90B
derived: sum of 3 quarters · filed 2021-02-17
$5.17B
derived: sum of 4 quarters · filed 2021-02-17
2018-12-31$1.39B
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17
$2.67B
derived: sum of 2 quarters · filed 2021-02-17
$3.94B
derived: sum of 3 quarters · filed 2021-02-17
$5.05B
10-K · filed 2021-02-17
$5.31B
10-K · filed 2019-02-19
2018-09-30$1.28B
10-Q · filed 2019-10-25
$1.34B
10-Q · filed 2018-11-06
$2.55B
derived: sum of 2 quarters · filed 2019-10-25
$3.66B
10-Q · filed 2019-10-25
$3.85B
10-Q · filed 2018-11-06
$4.89B
derived: sum of 4 quarters · filed 2020-02-19
2018-06-30$1.27B
10-Q · filed 2019-08-02
$1.33B
10-Q · filed 2018-07-25
$2.38B
10-Q · filed 2019-08-02
$2.51B
10-Q · filed 2018-07-25
$3.60B
derived: sum of 3 quarters · filed 2020-02-19
$4.94B
derived: sum of 4 quarters · filed 2020-02-19
2018-03-31$1.11B
10-Q · filed 2019-05-02
$1.18B
10-Q · filed 2018-04-27
$2.33B
derived: sum of 2 quarters · filed 2020-02-19
$3.67B
derived: sum of 3 quarters · filed 2020-02-19
$4.95B
derived: sum of 4 quarters · filed 2020-02-19
2017-12-31$1.23B
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19
$2.57B
derived: sum of 2 quarters · filed 2020-02-19
$3.84B
derived: sum of 3 quarters · filed 2020-02-19
$5.10B
10-K · filed 2020-02-19
$5.28B
10-K · filed 2018-02-20
2017-09-30$1.34B
10-Q · filed 2018-11-06
$1.32B
10-Q · filed 2017-10-27
$2.61B
derived: sum of 2 quarters · filed 2018-11-06
$3.87B
10-Q · filed 2018-11-06
$3.81B
10-Q · filed 2017-10-27
$5.12B
derived: sum of 4 quarters · filed 2019-10-24
2017-06-30$1.27B
10-Q · filed 2018-07-25
$1.25B
10-Q · filed 2017-07-28
$2.53B
10-Q · filed 2018-07-25
$2.49B
10-Q · filed 2017-07-28
$3.78B
derived: sum of 3 quarters · filed 2019-10-24
$5.01B
derived: sum of 4 quarters · filed 2019-10-24
2017-03-31$1.26B
10-Q · filed 2018-04-27
$1.24B
10-Q · filed 2017-05-01
$2.50B
derived: sum of 2 quarters · filed 2019-10-24
$3.74B
derived: sum of 3 quarters · filed 2019-10-24
$5.08B
derived: sum of 4 quarters · filed 2019-10-24
2016-12-31$1.25B
derived: 8-K 12 month − 10-Q 9 month · filed 2019-10-24
$2.48B
derived: sum of 2 quarters · filed 2019-10-24
$3.82B
derived: sum of 3 quarters · filed 2019-10-24
$5.04B
8-K · filed 2019-10-24
$5.24B
10-K · filed 2017-02-21
2016-09-30$1.24B
10-Q · filed 2017-10-27
$2.57B
derived: sum of 2 quarters · filed 2017-10-27
$3.79B
10-Q · filed 2017-10-27
$5.24B
derived: sum of 4 quarters · filed 2018-02-20
2016-06-30$1.34B
10-Q · filed 2017-07-28
$2.56B
10-Q · filed 2017-07-28
$4.00B
derived: sum of 3 quarters · filed 2018-02-20
$5.14B
derived: sum of 4 quarters · filed 2018-02-20
2016-03-31$1.22B
10-Q · filed 2017-05-01
$2.67B
derived: sum of 2 quarters · filed 2018-02-20
$3.81B
derived: sum of 3 quarters · filed 2018-02-20
$4.98B
derived: sum of 4 quarters · filed 2018-02-20
2015-12-31$1.44B
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20
$2.59B
derived: sum of 2 quarters · filed 2018-02-20
$3.76B
derived: sum of 3 quarters · filed 2018-02-20
$4.80B
10-K · filed 2018-02-20
2015-09-30$1.14B
10-Q · filed 2016-10-28
$2.31B
derived: sum of 2 quarters · filed 2016-10-28
$3.35B
10-Q · filed 2016-10-28
$4.54B
derived: sum of 4 quarters · filed 2017-02-21
2015-06-30$1.17B
10-Q · filed 2016-07-28
$2.21B
10-Q · filed 2016-07-28
$3.39B
derived: sum of 3 quarters · filed 2017-02-21
$4.64B
derived: sum of 4 quarters · filed 2017-02-21
2015-03-31$1.04B
10-Q · filed 2016-04-29
$2.23B
derived: sum of 2 quarters · filed 2017-02-21
$3.47B
derived: sum of 3 quarters · filed 2017-02-21
$4.66B
derived: sum of 4 quarters · filed 2017-02-21
2014-12-31$1.19B
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21
$2.43B
derived: sum of 2 quarters · filed 2017-02-21
$3.62B
derived: sum of 3 quarters · filed 2017-02-21
$4.73B
10-K · filed 2017-02-21
2014-09-30$1.24B
10-Q · filed 2015-10-30
$2.44B
derived: sum of 2 quarters · filed 2015-10-30
$3.55B
10-Q · filed 2015-10-30
$5.02B
derived: sum of 4 quarters · filed 2016-02-19
2014-06-30$1.20B
10-Q · filed 2015-07-30
$2.30B
10-Q · filed 2015-07-30
$3.78B
derived: sum of 3 quarters · filed 2016-02-19
$5.16B
derived: sum of 4 quarters · filed 2016-02-19
2014-03-31$1.11B
10-Q · filed 2015-04-30
$2.58B
derived: sum of 2 quarters · filed 2016-02-19
$3.96B
derived: sum of 3 quarters · filed 2016-02-19
$5.29B
derived: sum of 4 quarters · filed 2016-02-19
2013-12-31$1.48B
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19
$2.85B
derived: sum of 2 quarters · filed 2016-02-19
$4.18B
derived: sum of 3 quarters · filed 2016-02-19
$5.53B
10-K · filed 2016-02-19
2013-09-30$1.38B
10-Q · filed 2014-10-29
$2.71B
derived: sum of 2 quarters · filed 2014-10-29
$4.06B
10-Q · filed 2014-10-29
$5.52B
derived: sum of 4 quarters · filed 2015-02-19
2013-06-30$1.33B
10-Q · filed 2014-07-28
$2.68B
10-Q · filed 2014-07-28
$4.14B
derived: sum of 3 quarters · filed 2015-02-19
$5.48B
derived: sum of 4 quarters · filed 2015-02-19
2013-03-31$1.35B
10-Q · filed 2014-04-28
$2.81B
derived: sum of 2 quarters · filed 2015-02-19
$4.15B
derived: sum of 3 quarters · filed 2015-02-19
$5.47B
derived: sum of 4 quarters · filed 2015-02-19
2012-12-31$1.46B
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19
$2.81B
derived: sum of 2 quarters · filed 2015-02-19
$4.13B
derived: sum of 3 quarters · filed 2015-02-19
$5.28B
10-K · filed 2015-02-19
2012-09-30$1.34B
10-Q · filed 2013-10-30
$2.66B
derived: sum of 2 quarters · filed 2013-10-30
$3.81B
10-Q · filed 2013-10-30
$5.17B
derived: sum of 4 quarters · filed 2014-02-19
2012-06-30$1.32B
10-Q · filed 2013-07-26
$2.47B
10-Q · filed 2013-07-26
$3.83B
derived: sum of 3 quarters · filed 2014-02-19
$5.11B
derived: sum of 4 quarters · filed 2014-02-19
2012-03-31$1.15B
10-Q · filed 2013-04-26
$2.51B
derived: sum of 2 quarters · filed 2014-02-19
$3.79B
derived: sum of 3 quarters · filed 2014-02-19
$5.05B
derived: sum of 4 quarters · filed 2014-02-19
2011-12-31$1.36B
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19
$2.64B
derived: sum of 2 quarters · filed 2014-02-19
$3.90B
derived: sum of 3 quarters · filed 2014-02-19
$5.02B
10-K · filed 2014-02-19
2011-09-30$1.28B
10-Q · filed 2012-10-26
$2.54B
derived: sum of 2 quarters · filed 2012-10-26
$3.67B
10-Q · filed 2012-10-26
$5.10B
derived: sum of 4 quarters · filed 2013-02-21
2011-06-30$1.26B
10-Q · filed 2012-07-27
$2.38B
10-Q · filed 2012-07-27
$3.82B
derived: sum of 3 quarters · filed 2013-02-21
$5.04B
derived: sum of 4 quarters · filed 2013-02-21
2011-03-31$1.12B
10-Q · filed 2012-04-30
$2.56B
derived: sum of 2 quarters · filed 2013-02-21
$3.78B
derived: sum of 3 quarters · filed 2013-02-21
$4.97B
derived: sum of 4 quarters · filed 2013-02-21
2010-12-31$1.44B
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21
$2.66B
derived: sum of 2 quarters · filed 2013-02-21
$3.85B
derived: sum of 3 quarters · filed 2013-02-21
$4.88B
10-K · filed 2013-02-21
2010-09-30$1.22B
10-Q · filed 2011-10-28
$2.41B
derived: sum of 2 quarters · filed 2011-10-28
$3.45B
10-Q · filed 2011-10-28
$4.66B
derived: sum of 4 quarters · filed 2012-02-24
2010-06-30$1.19B
10-Q · filed 2011-07-29
$2.23B
10-Q · filed 2011-07-29
$3.44B
derived: sum of 3 quarters · filed 2012-02-24
$4.57B
derived: sum of 4 quarters · filed 2012-02-24
2010-03-31$1.04B
10-Q · filed 2011-04-29
$2.26B
derived: sum of 2 quarters · filed 2012-02-24
$3.38B
derived: sum of 3 quarters · filed 2012-02-24
$4.42B
derived: sum of 4 quarters · filed 2012-02-24
2009-12-31$1.22B
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24
$2.34B
derived: sum of 2 quarters · filed 2012-02-24
$3.38B
derived: sum of 3 quarters · filed 2012-02-24
$4.33B
10-K · filed 2012-02-24
2009-09-30$1.12B
10-Q · filed 2010-10-29
$2.16B
derived: sum of 2 quarters · filed 2010-10-29
$3.11B
10-Q · filed 2010-10-29
$4.17B
derived: sum of 4 quarters · filed 2011-02-22
2009-06-30$1.04B
10-Q/A · filed 2010-08-02
$1.99B
10-Q/A · filed 2010-08-02
$3.05B
derived: sum of 3 quarters · filed 2011-02-22
$4.00B
derived: sum of 4 quarters · filed 2011-02-22
2009-03-31$947.30M
10-Q · filed 2010-07-30
$2.01B
derived: sum of 2 quarters · filed 2011-02-22
$2.96B
derived: sum of 3 quarters · filed 2011-02-22
$3.91B
derived: sum of 4 quarters · filed 2011-02-22
2008-12-31$1.06B
derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-22
$2.01B
derived: sum of 2 quarters · filed 2011-02-22
$2.96B
derived: sum of 3 quarters · filed 2011-02-22
$3.84B
10-K · filed 2011-02-22
2008-09-30$953.00M
10-Q · filed 2009-10-30
$1.90B
derived: sum of 2 quarters · filed 2009-10-30
$2.78B
10-Q · filed 2009-10-30
2008-06-30$951.50M
10-Q · filed 2009-07-31
$1.83B
10-Q · filed 2009-07-31
2007-12-31$3.49B
10-K · filed 2010-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
Akari Therapeutics Plc (AKTX)$1,527.991B-47,921.42
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
AbbVie Inc. (ABBV)United States$468.180B70.37
Merck & Co., Inc. (MRK)United States$365.215B99.96
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94